Urine analysis and protein networking identify met as a marker of metastatic prostate cancer

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4292-4298

  Russo, Andrea L ^a,b   Jedlicka, Kimberly ^c   Wernick, Meredith ^a   McNally, Debbie ^a   Kirk, Melissa ^a   Sproull, Mary ^a   Smith, Sharon ^a   Shankavaram, Uma ^a   Kaushal, Aradhana ^a   Figg, William D ^c   Dahut, William ^c   Citrin, Deborah ^a   Bottaro, Donald P ^c   Albert, Paul S ^a   Tofilon, Philip J ^d   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Medical Oncology Branch   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; SIGNAL TRANSDUCTION; TWO HYBRID SYSTEM; URINALYSIS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; ROC CURVE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINALYSIS;

EID: 67650360799     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0599     Document Type: Article

References (27)

1. Jemal A, S iegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2007.
3. Leibovici D, Spiess PE, Agarwal PK, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007;109:198-204.
4. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. JNatl Cancer Inst 2007;99:526-32.
5. Sandblom G, Ladjevardi S, Garmo H, Varenhorst E. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate. Cancer 2008;112:813-9.
6. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. JUrol 1994;151:1558-64.
7. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-25.
8. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67:967-75.
9. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12:4154-62.
10. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8.
11. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of theMet receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-7.
12. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. JUrol 2001;165:1325-8.
13. McShane LM, Altman DG, Sauerbrei W,Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
14. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 2005;173:342-59.
15. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
16. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68: 645-9.
17. Nakashiro K, Hara S, Shinohara Y, et al. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol 2004;165:533-40.
18. Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 2003;10:1149-53.
19. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev 2003;4:915-25.
20. van der Voort R,Taher TE, Wielenga VJ, et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem1999;274:6499-506.
21. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Invest Drugs 2008;17:997-1011.
22. Dietrich S, Abou-Rebyeh F, Brohmann H, et al. The role of SF/HGF and c-Met in the development of skeletal muscle. Development 1999;126: 1621 - 9.
23. Ponzetto C, Zhen Z, Audero E, et al. Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation andmotility. JBiol Chem 1996;271:14119-23.
24. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391: 285-8.
25. Sato N, Sadar MD, Bruchovsky N, et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272: 17485 - 94.
26. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006;25:2367-78.
27. Yu YP, Luo JH. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res 2006;66:7414-9.